The Renee Maria Saliby #kidneycancer biomarker paper in Cancer Cell is online with a detailed tweetorial: consistent benefit across all subgroups of IO-based therapies over VEGF TKI OncoAlert Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber Yale Cancer Center #WCRM #DANA9

#Teamwork with amazing collaborators

The phase 3 CheckMate 914 trial revealed that nivolumab did not achieve the primary goal of improving disease-free survival vs placebo in patients with localized #RCC who were at an increased risk of relapse after nephrectomy. #KCSM | Robert Motzer MD

targetedonc.com/view/adjuvant-…

Humbled and thrilled to receive the Burroughs Wellcome Fund CAMS. I am excited to meet these incredible awardees. Thanks to all my mentors for their unwavering support. A big shout out to Charles Sawyers for his mentorship in the maturation of my career as a physician–scientist Memorial Sloan Kettering Cancer Center

Masterful presentation by Robert Motzer MD reporting subgroup analyses from #CheckMate914 (part A).
Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 OncoAlert

A smaller difference by the number of cycles received, likely not accounting for the absence of an effect in the overall trial!

ASCO #ASCO23

Dr. Robert Motzer MD with an important presentation of #CHECKMATE914 Part A subgroup analyses.
ASCO #ASCO23

While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit

Ab#4518 #ASCO23 ASCO Kidney Cancer
Phase 2 results of lenvatinib + pembrolizumab in pts with non-clear cell #kidneycancer 49% ORR in a 158 pt cohort of papillary, unclassified, chromophobe, translocation RCC. Laurence Albiges meetings.asco.org/abstracts-pres…

RR continue to climb in Chung-Han Lee 李宗翰, MD/PhD Robert Motzer MD Memorial Sloan Kettering Cancer Center trial of cabo/nivo in nccRCC. Need to establish role of TKI/IO in nccRCC - best way to do this is to support trials like SWOG Cancer Research Network 2200 & #STELLAR304 . @uromigos Brian Rini, MD Tom Powles ASCO #ASCO23

1/ Results from #COSMIC -313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22

Thread 🧵==>

nejm.org/doi/full/10.10…

Congrats to Robert Motzer MD and team on their recent study in NEJM! Phase 3 results showed progression-free survival for people with #kidneycancer was significantly longer with cabozantinib plus nivolumab and ipilimumab than with nivolumab and ipilimumab alone. nejm.org/doi/full/10.10…

The deadline is extended!

KidneyCAN OncoAlert

#KCRS23

Tom Powles Toni Choueiri, MD Brian Rini, MD Robert Motzer MD And your missing the best, the 4 year OS eat al. From the CLEAR trial that I am presenting. Stay tuned.

Huge congrats to Toni Choueiri, MD & team for paving the way towards a new regimen for #kidneycancer in this The Lancet Oncology paper! Neeraj Agarwal, MD, FASCO Petros Grivas Rana McKay KCCure KidneyCAN Kidney Cancer

Dr. Martin Voss from Memorial Sloan Kettering Cancer Center, 2021 KCCure #chromophobe research grant recipient, updated pts on the potential of IL-15 as tx for this rare subtype of #kidneycancer . Fingers crossed that this will lead to the first ever chRCC specific clinical trial!

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations

buff.ly/42KOq0o

Chung-Han Lee 李宗翰, MD/PhD Ritesh Kotecha David H Aggen, MD PhD Neil Shah Dr. Darren Feldman Robert Motzer MD

With Yuji Miura in the renal cancer session in 🇯🇵 . PD-1/VEGF combos ⬆️ RR in papillary RCC. Dr Juninho Inokuchi thinks they should be a standard of care as single agent TKI not good enough. Thr SAMETA trial of MET inhibition & durvalumab in MET +ve is important #JSMO2023

1/ Excited to announce updates from the #CLEAR trial in The Lancet Oncology: A long-term follow-up of lenvatinib + pembrolizumab vs sunitinib in this brief tweetorial:

And yet another win for patients with renal cell carcinoma #RCC

sciencedirect.com/science/articl…

OncoAlert ASCO ESMO - Eur. Oncology

Current Issue: Progression-free Survival After Second Line of Therapy for Metastatic ccRCC in Patients Treated with First-line Immunotherapy Combinations

buff.ly/3Uf2NoX

Chung-Han Lee 李宗翰, MD/PhD Ritesh Kotecha David H Aggen, MD PhD Neil Shah Dr. Darren Feldman Robert Motzer MD

#MedTwitter #UroSoMe

🔘 On The Lancet - Assessing the efficacy and safety of adjuvant nivolumab + ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914)

#immunotherapy #kidneycancer

thelancet.com/journals/lance…

Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the The Lancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could be the main culprit. Thank you for all the patients/families who believe in thelancet.com/journals/lance…